These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Characteristic and effective usage of adriamycin]. Horiuchi K; Akimoto M Gan To Kagaku Ryoho; 1996 Dec; 23(14):1916-9. PubMed ID: 8978797 [TBL] [Abstract][Full Text] [Related]
23. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer]. Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921 [No Abstract] [Full Text] [Related]
25. The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer. Br J Urol; 1994 Jun; 73(6):632-8. PubMed ID: 8032829 [TBL] [Abstract][Full Text] [Related]
26. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group. Debruyne FM; van der Meijden AP; Franssen MP Prog Clin Biol Res; 1989; 303():435-46. PubMed ID: 2506556 [No Abstract] [Full Text] [Related]
27. Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group. van der Meijden AP; Kurth KH; Oosterlinck W; Debruyne FM Cancer Chemother Pharmacol; 1992; 30 Suppl():S95-8. PubMed ID: 1394828 [TBL] [Abstract][Full Text] [Related]
28. Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. Lum BL; Torti FM J Natl Cancer Inst; 1991 May; 83(10):682-94. PubMed ID: 1827165 [TBL] [Abstract][Full Text] [Related]
29. The 4th study of prophylactic intravesical chemotherapy with adriamycin in the treatment of superficial bladder cancer: the experience of the Japanese Urological Cancer Research Group for Adriamycin. Matsumura Y; Akaza H; Isaka S; Kagawa S; Koiso K; Kotake T; Machida T; Niijima T; Obata K; Ohashi Y Cancer Chemother Pharmacol; 1992; 30 Suppl():S10-4. PubMed ID: 1394809 [TBL] [Abstract][Full Text] [Related]
30. Treatment of bladder cancer with intravesical instillation of adriamycin. Pavone-Macaluso M; Ingargiola GB; Tripi M; Lamartina M Prog Clin Biol Res; 1984; 162B():181-91. PubMed ID: 6390445 [TBL] [Abstract][Full Text] [Related]
31. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. Zincke H; Utz DC; Taylor WF; Myers RP; Leary FJ J Urol; 1983 Mar; 129(3):505-9. PubMed ID: 6403716 [TBL] [Abstract][Full Text] [Related]
32. Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone. Schulman CC; Robinson M; Denis L; Smith P; Viggiano G; de Pauw M; Dalesio O; Sylvester R Eur Urol; 1982; 8(4):207-12. PubMed ID: 6807679 [TBL] [Abstract][Full Text] [Related]
33. Cytostatic intravesical instillation in patients with superficial bladder carcinoma for the prevention of recurrent tumors. Huland H; Klöppel G; Otto U; Feddersen I; Brachmann W; Hubmann H; Kaufmann J; Knipper W; Lantzius-Beninga F Eur Urol; 1988; 14(3):202-6. PubMed ID: 3133216 [TBL] [Abstract][Full Text] [Related]
34. [Chemotherapy of bladder tumors. Indications and value of loco-regional and systemic application]. Pavone-Macaluso M Urologe A; 1983 Sep; 22 Suppl():325-31. PubMed ID: 6195795 [TBL] [Abstract][Full Text] [Related]
35. Intravesical doxorubicin for the prophylaxis of superficial bladder tumors. A multicenter study. Blinst Italian Cooperative Group. Cancer; 1984 Aug; 54(4):756-61. PubMed ID: 6378357 [TBL] [Abstract][Full Text] [Related]
36. Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder. Kurth KH; Bouffioux C; Sylvester R; de Pauw M Prog Clin Biol Res; 1988; 269():525-37. PubMed ID: 3134663 [No Abstract] [Full Text] [Related]
37. [Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin]. Hinotsu S; Akaza H; Isaka S; Kagawa S; Koiso K; Kotake T; Machida T; Matsumura Y; Niijima T; Obata K; Ohashi Y; Ohe H; Shimazaki J; Tashiro K; Gan To Kagaku Ryoho; 2002 Jan; 29(1):73-80. PubMed ID: 11816482 [TBL] [Abstract][Full Text] [Related]